Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004)

Anthony Traboulsee,Fred Lublin,Hideki Garren,Peter Chin,Paulo Fontoura,Amit Bar-Or,Krzysztof Selmaj,Douglas Arnold,Gaelle Klingelschmitt,Hans-Peter Hartung,Stephen Hauser,Giancarlo Comi,Ludwig Kappos,Donna Masterman

doi:10.1212/wnl.86.16_supplement.pl02.004

Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004)

Anthony Traboulsee, Fred Lublin + Show 12 more

https://doi.org/10.1212/wnl.86.16_supplement.pl02.004

Copy DOI

Journal: Neurology	Publication Date: Apr 5, 2016
Citations: 6

Affiliation: University of British Columbia, Icahn School of Medicine at Mount Sinai, Roche (Switzerland), Montreal Neurological Institute and Hospital, Medical University of Lodz, McGill University, Heinrich Heine University Düsseldorf, Vita-Salute San Raffaele University, University Hospital of Basel

#No Evidence Of Disease Activity #Multiple Sclerosis + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Neurology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.